10x基因组学比2025年Q3的预期收入要高,提高了Q4指导,股票增长了13.1%。 10x Genomics beat earnings expectations in Q3 2025, raised Q4 guidance, and saw stock rise 13.1%.

10x 基因组学报告说,2025年的Q3收入为1.49亿美元,比同年略有下降,但超过预期4.6%。 10x Genomics reported Q3 2025 earnings with revenue of $149 million, slightly down year-over-year but exceeding expectations by 4.6%. 该公司公布的《公认会计原则》损失为每股0.22美元,殴打估计损失22.3%。 The company posted a GAAP loss of $0.22 per share, beating estimates by 22.3%. 它将其2025年Q4收入指导提高到1.56亿美元,表明需求强劲,并报告业务利润率有所改善。 It raised its Q4 2025 revenue guidance to $156 million, signaling stronger demand, and reported improved operating margins. 由于其核心生命科学领域的业绩好于预期, 股票增长了13.1%. The stock rose 13.1% after the release, driven by better-than-expected results and signs of recovery in its core life sciences segments.